Simple and safe heparin regimen for acute ischaemia

Area of Science:

• Neurology
• Vascular Medicine
• Pharmacology

Background:

• The optimal anticoagulation strategy for acute ischemic cerebrovascular disease remains unclear.
• Establishing a favorable risk/benefit ratio for anticoagulation is crucial.

Purpose of the Study:

• To evaluate the safety and efficacy of an intermittent intravenous heparin regimen in patients with acute ischemic cerebrovascular disease.
• To determine if this regimen is a viable alternative when continuous heparin infusion or frequent clotting time monitoring is not feasible.

Main Methods:

• A prospective study involving 50 patients (mean age 57 years) with ischemic cerebrovascular disease.
• Patients received a simple, safe intermittent intravenous heparin regimen of 20,000 IU daily.
• The study included patients with cardiogenic embolism, recurrent transient ischemic attacks, and progressive cerebral infarcts, with blood pressures ranging from normal to severe hypertension.

Main Results:

• Two patients experienced recurrences of cerebral thromboembolism.
• No bleeding complications were observed in any of the patients.
• The average duration of heparin exposure was 6.4 days.

Conclusions:

• Intermittent intravenous heparin (20,000 IU daily) is a safe and efficient anticoagulation method for acute ischemic cerebrovascular disease.
• This regimen is particularly useful when continuous heparin infusion or routine monitoring of clotting times is not practical.
• The study suggests a favorable safety profile with minimal thromboembolic recurrences and no bleeding events.